Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-NEFL Antibody (R3A04)

Catalog #:   RHC23303 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC, WB
Accession: P07196
Overview

Catalog No.

RHC23303

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

NEFL, Neurofilament light polypeptide, 68 kDa neurofilament protein, NF68, Neurofilament triplet L protein, NF-L, NFL

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P07196

Applications

ELISA, FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3A04

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Jurkat cells using NEFL mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using NEFL mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human lung cancer tissues using NEFL mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human brain tissues using NEFL mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using NEFL mouse mAb against Hela (1) and Jurkat (2) cell lysate.
  • Western blot
    Western blot analysis using NEFL mouse mAb against Hela (1) and Jurkat (2) cell lysate.
References

Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis., PMID:40510879

Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab., PMID:40345115

Serum angiotensin type-1 receptor autoantibodies and neurofilament light chain as markers of neuroaxonal damage in post-COVID patients., PMID:40330487

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis., PMID:40300121

The utility of serum neurofilament light chain in MOGAD: Current insights and future directions., PMID:40220725

Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis optica spectrum disorders versus multiple sclerosis., PMID:40175444

Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation., PMID:40056413

A turn-on fluorescent immunosensor for neurodegenerative disease related neurofilament light chain protein., PMID:39904887

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use., PMID:39893752

Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy., PMID:39874744

CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity., PMID:39869499

Neurofilament light chain levels in neuronal surface antibody-associated autoimmune encephalitis: a systematic review and meta-analysis., PMID:39856041

Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis., PMID:39842345

Neuromuscular junction visualization in paraffin-embedded thyroarytenoid muscle sections: Expanding options beyond frozen section analysis., PMID:39780862

Immunohistochemical labeling of ongoing axonal degeneration 10 days following cervical contusion spinal cord injury in the rat., PMID:39753895

Serum glycobiomarkers for chronic inflammatory demyelinating polyneuropathy., PMID:39722472

Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder., PMID:39714824

Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease., PMID:39705633

Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients., PMID:39684862

Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis., PMID:39606235

Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy., PMID:39601182

Cerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis., PMID:39575564

Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis., PMID:39556523

Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis., PMID:39536291

De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study., PMID:39510011

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients., PMID:39494701

Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS., PMID:39462090

Autoimmune astrocytopathy double negative for AQP4-IgG and GFAP-IgG: Retrospective research of clinical practice, biomarkers, and pathology., PMID:39279053

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms., PMID:39237493

Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis., PMID:39224593

An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease., PMID:39048548

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients., PMID:38909525

Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study., PMID:38901371

Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment., PMID:38889559

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres., PMID:38877721

Electrochemical Biosensor for Point-of-Care Testing of Low-Abundance Biomarkers of Neurological Diseases., PMID:38865206

Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease., PMID:38807603

The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis., PMID:38777960

Autoantibody Profile Emerged Years Before Multiple Sclerosis Diagnosis., PMID:38758535

Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study., PMID:38754397

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial., PMID:38683602

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis., PMID:38648580

An autoantibody signature predictive for multiple sclerosis., PMID:38641750

Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder., PMID:38564996

Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases., PMID:38007650

Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR)., PMID:37739331

High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases., PMID:37031551

Nogo-A Regulates the Fate of Human Dental Pulp Stem Cells toward Osteogenic, Adipogenic, and Neurogenic Differentiation., PMID:36359811

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis., PMID:35025605

Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation., PMID:34985329

Datasheet

Document Download

Anti-NEFL Antibody (R3A04).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-NEFL Antibody (R3A04) [RHC23303]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only